id: NEW:criminal_justice_officer_stigma_toward_moud_to_sud_medication_treatment_rate_oud
name: Probation/Parole Officer Stigma Toward Buprenorphine and Methadone â†’ OUD Medication Treatment Rate
from_node:
  node_id: NEW:criminal_justice_officer_stigma_toward_moud
  node_name: Probation/Parole Officer Stigma Toward Buprenorphine and Methadone
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate
direction: negative
category: social_environment
mechanism_pathway:
- 'Step 1: Probation and parole officers hold stigmatizing attitudes toward buprenorphine and methadone
  (agonist medications)'
- 'Step 2: Officers may discourage or create barriers to individuals seeking these specific MOUD options'
- 'Step 3: Justice-involved individuals face reduced access to full range of evidence-based treatment
  options'
- 'Step 4: Lower overall MOUD utilization and suboptimal treatment matching'
- 'Step 5: Reduced recovery and remission outcomes among justice-involved individuals with OUD'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Marisa D Booty et al. 2023. "Barriers and facilitators to the use of medication for
    opioid use disorder within the criminal justice system: Perspectives from clinicians.." https://doi.org/10.1016/j.josat.2023.209051'
  supporting_citations:
  - Additional citations require full-text access - qualitative interview study with 25 social service
    clinicians
  - Study references heightened overdose risk upon release from incarceration (citation in full text)
  - Study references need to address stigma among probation and parole officers (citation in full text)
  doi: 10.1016/j.josat.2023.209051
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Attitudinal barriers among probation and parole officers, specifically stigma toward buprenorphine
  and methadone, reduce access to the full continuum of MOUD options for justice-involved individuals
  with OUD.
quantitative_effects:
  sample_size: 25
moderators:
- name: medication_type
  direction: strengthens
  strength: strong
  description: Stigma specifically directed toward buprenorphine and methadone (agonist therapies) rather
    than extended-release naltrexone (antagonist therapy)
structural_competency:
  equity_implications: This mechanism demonstrates how institutional attitudes within the criminal justice
    system create structural barriers to evidence-based healthcare. The differential stigma toward agonist
    vs antagonist therapies reflects broader societal misconceptions about medication-assisted treatment.
    Addressing this requires system-level training and policy change rather than individual-level interventions.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.772020'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
